Finding gems in India

Why Agios partnered with India’s Aurigene to tackle new cancer metabolism target

For Agios Pharmaceuticals Inc., the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part of a strategy of hunting for compounds in India or anywhere else.

For Aurigene, though, the deal is one step among many in an ongoing transition into a biotech with commercial ambitions.

On April 27, the partners announced that Aurigene had granted Agios exclusive rights to develop and commercialize a portfolio of small molecules that hit an undisclosed cancer metabolism target. The deal included

Read the full 962 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers